TG Therapeutics reported impressive first-quarter results for its multiple sclerosis treatment BRIUMVI, with U.S. net sales reaching $119.7 million—an astounding 137% year-over-year growth. This surge in sales prompted the company to raise its full-year revenue guidance from $525 million to $560 million, indicating strong momentum in patient enrollment and prescription persistence. Notably, repeat prescriptions have now outpaced new ones for the first time, reflecting increasing confidence from healthcare providers.
The growth in BRIUMVI’s market share, now estimated at 25% of the IV segment, underscores its competitive position despite a crowded marketplace. The company is also preparing for pivotal trials for a subcutaneous formulation, which could enhance patient accessibility and adherence. With operating expenses remaining stable and a cash reserve of $276 million, TG is well-positioned to support its ongoing clinical and commercialization efforts.
For market professionals, the key takeaway is TG Therapeutics’ robust sales performance and strategic initiatives that could further solidify BRIUMVI’s position in the market, making it a stock to watch in the biotech sector.
Source: fool.com